Regent Pacific GroupRPGLF 12 Return-on-Tangible-Asset is -764.75% as of Dec. 2025. GuruFocus rates RPGLF with a GF Score™ of 12/100. The stock has 7 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Regent Pacific Group ranks worse than 98.71% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Regent Pacific Group's annualizedNet Income for the quarter that ended in Dec. 2025 was $-4.99 Mil. Regent Pacific Group's average total tangible assets for the quarter that ended in Dec. 2025 was $0.65 Mil. Therefore, Regent Pacific Group's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -764.75%.
The historical rank and industry rank for Regent Pacific Group's Return-on-Tangible-Asset or its related term are showing as below:
RPGLF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1207.83 Med: -364.13 Max: -9.34
Current: -738.62
During the past 13 years, Regent Pacific Group's highest Return-on-Tangible-Asset was -9.34%. The lowest was -1207.83%. And the median was -364.13%.
RPGLF's Return-on-Tangible-Asset is ranked worse than 98.71% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs RPGLF: -738.62
Regent Pacific Group (OTCPK:RPGLF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Regent Pacific Group Return-on-Tangible-Asset Related Terms
Regent Pacific Group Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Regent Pacific Group's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regent Pacific Group Return-on-Tangible-Asset Chart
RPGLF vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Regent Pacific Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regent Pacific Group Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regent Pacific Group's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Regent Pacific Group's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -764.75% mean?
Regent Pacific Group (RPGLF) has a Return-on-Tangible-Asset of -764.75% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Regent Pacific Group and its competitors. According to the industry distribution chart, Regent Pacific Group ranks #992 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 98.7%.
Is Regent Pacific Group's Return-on-Tangible-Asset too high?
Regent Pacific Group's current Return-on-Tangible-Asset is -764.75%. Based on the distribution chart, Regent Pacific Group ranks #992 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Regent Pacific Group has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Regent Pacific Group's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Regent Pacific Group ranks #992 out of 1005 companies for Return-on-Tangible-Asset. This places Regent Pacific Group in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Regent Pacific Group and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regent Pacific Group's current Return-on-Tangible-Asset is -764.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regent Pacific Group stock overvalued right now?
Regent Pacific Group (RPGLF) has a current Return-on-Tangible-Asset of -764.75%. The current Return-on-Tangible-Asset is -764.75%. Regent Pacific Group's overall GF Score™ is 12/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Regent Pacific Group (RPGLF), the current Return-on-Tangible-Asset is -764.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Geographically, the Europe; U.S.; and Asia Pacific. It derives maximum revenue from Europe.
12GF Score
Get the complete analysis for RPGLF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPGLF has been successfully added to your 
